Targeting Angiogenesis in Bladder Cancer

被引：31

作者：

Elfiky, Aymen A. ^{[1
]}

Rosenberg, Jonathan E. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

来源：

CURRENT ONCOLOGY REPORTS | 2009年 / 11卷 / 03期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMA; RECEPTOR MONOCLONAL-ANTIBODY; ONCOLOGY-GROUP ECOG; MICROVESSEL DENSITY; FACTOR EXPRESSION; INTERSTITIAL HYPERTENSION; INHIBITOR TNP-470; PROGNOSTIC VALUE; BREAST-CANCER;

D O I：

10.1007/s11912-009-0034-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In most cases, death from bladder cancer results from metastatic disease. Understanding the closely linked mechanisms of invasion, metastasis, and angiogenesis in bladder cancer has allowed development of new therapeutic strategies that may lead to improvements in patient survival. Vascular endothelial growth factor levels appear to be prognostic for outcomes in advanced bladder cancer, and preclinical evaluation of angiogenesis inhibition demonstrates anticancer activity. Antiangiogenic agents such as sunitinib, sorafenib, and bevacizumab are being tested in advanced bladder cancer. This review highlights the key developments in antiangiogenic therapy as it relates to bladder cancer treatment.

引用

页码：244 / 249

页数：6

共 58 条

[51] INFLUENCE OF AN ANTI-ANGIOGENIC TREATMENT ON 9L GLIOSARCOMA - OXYGENATION AND RESPONSE TO CYTOTOXIC THERAPY [J].

TEICHER, BA ;

HOLDEN, SA ;

ARA, G ;

DUPUIS, NP ;

LIU, F ;

YUAN, J ;

IKEBE, M ;

KAKEJI, Y .

INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) :732-737

[52] Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study [J].

von der Maase, H ;

Hansen, SW ;

Roberts, JT ;

Dogliotti, L ;

Oliver, T ;

Moore, MJ ;

Bodrogi, I ;

Albers, P ;

Knuth, A ;

Lippert, CM ;

Kerbrat, P ;

Rovira, PS ;

Wersall, P ;

Cleall, SP ;

Roychowdhury, DF ;

Tomlin, I ;

Visseren-Grul, CM ;

Conte, PF .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3068-3077

[53] Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006) [J].

von der Maase, Hans ;

Sengelov, Lisa ;

Roberts, James T. ;

Ricci, Sergio ;

Dogliotti, Luigi ;

Oliver, T. ;

Moore, Malcolm J. ;

Zimmermann, Annamaria ;

Arning, Michael .

ANNALS OF ONCOLOGY, 2011, 22 (11) :2536-2536

[54] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

[55] Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [J].

Willett, CG ;

Boucher, Y ;

di Tomaso, E ;

Duda, DG ;

Munn, LL ;

Tong, RT ;

Chung, DC ;

Sahani, DV ;

Kalva, SP ;

Kozin, SV ;

Mino, M ;

Cohen, KS ;

Scadden, DT ;

Hartford, AC ;

Fischman, AJ ;

Clark, JW ;

Ryan, DP ;

Zhu, AX ;

Blaszkowsky, LS ;

Chen, HX ;

Shellito, PC ;

Lauwers, GY ;

Jain, RK .

NATURE MEDICINE, 2004, 10 (02) :145-147

[56] VEGF receptor expression and signaling in human bladder tumors [J].

Wu, WC ;

Shu, XD ;

Hovsepyan, H ;

Mosteller, RD ;

Broek, D .

ONCOGENE, 2003, 22 (22) :3361-3370

[57] Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer [J].

Xia, GB ;

Kumar, SR ;

Hawes, D ;

Cai, J ;

Hassanieh, L ;

Groshen, S ;

Zhu, ST ;

Masood, R ;

Quinn, DI ;

Broek, D ;

Stein, JP ;

Gill, PS .

JOURNAL OF UROLOGY, 2006, 175 (04) :1245-1252

[58] The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression [J].

Yang, CC ;

Chu, KC ;

Yeh, WM .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (01) :1-6

← 1 2 3 4 5 6 →